At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 181 enrolled
Drug / intervention
LIK066 +1 moredrug
Likely dose
LIK066 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Parallel Group, 2-part Study Investigating the Effect of LIK066 on Body Weight in Dysglycemic (Prediabetes or Type 2 Diabetes) and Normoglycemic Patients With Elevated Body Mass Index
In Brief
A Phase 2 clinical trial evaluating LIK066 and Placebo for Elevated Body Mass Index. Completed, enrolled 181 participants across 1 site.
Detailed Summary
A 12-week study to assess LIK066 effect on body weight in diabetics, prediabetics and normoglycemic patients with elevated body mass index (BMI)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsElevated Body Mass Index
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJun 2015
First PostedJun 2015
Primary CompletionApr 2016
TodayJul 2026
First PostedJun 12, 2015
Enrollment StartJun 5, 2015
Primary CompletionApr 4, 2016
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 11.1 years ago
Interventions
LIK066drug
LIK066 25 mg tablets
Placebodrug
Matching placebo tablets